3,6-dimethylimidazo[1,2-a]pyridine | 78132-62-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3,6-dimethylimidazo[1,2-a]pyridine
• 英文别名: 3,6-dimethylimidazo[1,2-α]pyridine
• CAS: 78132-62-4
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: VVWRVGQVEMXVQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,6-dimethylimidazo[1,2-a]pyridine 、 碘甲烷 以 硝基苯 为溶剂， 生成 1,3,6-Trimethyl-imidazo[1,2-a]pyridin-1-ium; iodide
  参考文献：
  名称：

  第二次世界大战的传播：第二次世界大战：对贵重赛道距离的影响

  摘要：

  描述了烷基和二烷基咪唑并[1,2-a]吡啶对甲基碘的定量亲核反应性。在一系列单甲基衍生物中，最活化的是7-甲基化合物，最失活的是8-甲基化合物。在不存在分子内空间相互作用的情况下，两种烷基取代基对烷基化速率的影响是加和的。相反，对于周围的二取代的衍生物观察到N 1的失活，并且该失活随着取代基的大小而增加。提出了这些电子和空间效应的解释。

  DOI：

  10.1016/s0040-4020(01)97720-8
• 作为产物：
  描述：

  5-methyl-N-(prop-2-yn-1-yl)pyridin-2-amine 以 水 为溶剂， 反应 1.0h， 以92%的产率得到3,6-dimethylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  Synthesis of Imidazo[1,2-a]pyridines: “Water-Mediated” Hydroamination and Silver-Catalyzed Aminooxygenation

  摘要：

  Aqueous syntheses of methylimidazo[1,2-a]pyridines without any deliberate addition of catalyst are reported. Imidazo[1,2-a]pyrazine and imidazo[2,1-a]isoquinoline were also obtained in good yields under similar conditions. With acetonitrile as solvent, Ag-catalyzed intra-molecular aminooxygenation produced imidazo[1,2-a]pyridine-3-carbaldehydes in moderate to good yields.

  DOI：

  10.1021/jo3025303

文献信息

• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2015103137A1

  公开（公告）日：2015-07-09

  Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.

  提供具有公式I的化合物或其立体异构体、互变异构体或药用可接受盐，这些化合物用于治疗疾病。公开了使用公式I的化合物或其立体异构体、互变异构体或药用可接受盐，用于体外、原位和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• [EN] COMPOUNDS TARGETING PRMT5<br/>[FR] COMPOSÉS CIBLANT PRMT5
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2020205867A1

  公开（公告）日：2020-10-08

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本文提供了式（I）的化合物或其药用盐，包括含有本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物以及合成这些化合物的方法。本文还提供了使用式（I）的化合物或其药用盐治疗疾病和/或症状的方法。
• Retinoid x receptor modulators
  申请人：Gardinier M. Kevin

  公开号：US20080090860A1

  公开（公告）日：2008-04-17

  The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof.

  本发明涉及由结构式I表示的化合物及其药学上可接受的盐、溶剂合物和水合物。本发明还涉及制备由结构式I表示的化合物及其药学上可接受的盐、溶剂合物和水合物的医药组合物、使用方法和制备方法。
• Organic Compounds
  申请人：Shaw Duncan

  公开号：US20100210641A1

  公开（公告）日：2010-08-19

  Compounds of formula I: in free or salt or solvate form, where R 1 , R 2 , R 3 and R 20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.

  式I的化合物：以自由或盐或溶剂形式存在，其中R1，R2，R3和R20具有规范中指定的含义，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的方法。这些化合物对于治疗炎症或阻塞性呼吸道疾病，如肺动脉高压，肺纤维化，肝纤维化，癌症，肌肉疾病，如肌肉萎缩和肌肉营养不良，以及全身性骨骼疾病，如骨质疏松症非常有用。
• BICYCLIC COMPOUND
  申请人：Kamata Makoto

  公开号：US20120010247A1

  公开（公告）日：2012-01-12

  The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有ACC抑制作用的化合物，其可用作预防或治疗肥胖症、糖尿病、高血压、高脂血症、心衰、糖尿病并发症、代谢综合征、肌肉萎缩、癌症等的药物，并具有优越的疗效。本发明涉及一种由式(I)表示的化合物，其中每个符号如规范中所定义，或其盐。